For physicians - Convalescent Plasma COVID-19 (Coronavirus) Treatment

For physicians

This section contains historical reference information and links to published works produced from the knowledge and data garnered in the Expanded Access Program (EAP) for the treatment of COVID-19.

How to order and administer high titer convalescent plasma Convalescent plasma evidence update Publications Sample data entry forms FDA fact sheet: Risks and benefits of convalescent plasma (PDF)

EAP vs. EUA: What you need to know

This document (PDF) outlines the differences between an expanded access program and emergency use authorization.

The Expanded Access Program team is documenting their research findings related to convalescent plasma

Publications

Convalescent Plasma COVID-19 Course

Video recordings

Protocol

Questions commonly asked about the Expanded Access Program to Emergency Use Authorization transition

Go to the FAQ pages.

IRB Information

Each local PI is responsible for completing of all study forms and documents in a timely manner. Completion of all forms is required as part of the agreement to participate in the program, statement of investigator commitments and in compliance with federal regulations.

If you or your hospital have questions about this, email uscovidplasma@mayo.edu.